[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576540":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":42,"overallOfficials":52,"centralContacts":56,"locations":62,"responsibleParty":223,"collaborators":11,"id":225,"slug":11,"hasResults":226,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":11,"eligibilityCriteria":230,"healthyVolunteers":226,"sex":231,"minAge":232,"maxAge":11,"enrollmentInfo":233,"targetDuration":11,"studyType":236,"phases":237,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":65,"whyStopped":11,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},{"fullName":5,"class":6},"Neurocrine Biosciences","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56",null,"Baseline, Day 56",[14,16],{"measure":15,"description":11,"timeFrame":12},"Change from Baseline in Sheehan Disability Scale (SDS) Total Score at Day 56",{"measure":17,"description":11,"timeFrame":12},"Change from Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Day 56",{"allocation":19,"interventionModel":20,"interventionModelDescription":11,"primaryPurpose":21,"observationalModel":11,"timePerspective":11,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":11,"whoMasked":24},"QUADRUPLE",[25,26,27,28],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"NBI-1065845","EXPERIMENTAL","NBI-1065845 administered orally once a day.",[35],"Drug: NBI-1065845",{"label":37,"type":38,"description":39,"interventionNames":40},"Placebo","PLACEBO_COMPARATOR","Placebo identical in appearance to NBI-1065845 will be administered orally once a day.",[41],"Drug: Placebo",[43,49],{"type":44,"name":31,"description":45,"armGroupLabels":46,"otherNames":47},"DRUG","NBI-1065845 tablets",[31],[48],"TAK-653",{"type":44,"name":37,"description":50,"armGroupLabels":51,"otherNames":11},"Matching placebo tablets",[37],[53],{"name":54,"affiliation":5,"role":55},"Clinical Development Lead","STUDY_DIRECTOR",[57],{"name":58,"role":59,"phone":60,"phoneExt":11,"email":61},"Neurocrine Medical Information Call Center","CONTACT","1-877-641-3461","medinfo@neurocrine.com",[63,77,87,95,103,111,119,128,136,145,154,163,172,180,189,197,206,214],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":11},"Neurocrine Clinical Site","RECRUITING","Little Rock","Arkansas","72204","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-92.28959,34.74648,{"lat":75,"lon":74},{"facility":64,"status":78,"city":79,"state":80,"zip":81,"country":69,"countryCode":70,"cosmosGeoPoint":82,"geoPoint":86,"contacts":11},"COMPLETED","Garden Grove","California","92844",{"type":72,"coordinates":83},[84,85],-117.94145,33.77391,{"lat":85,"lon":84},{"facility":64,"status":65,"city":88,"state":80,"zip":89,"country":69,"countryCode":70,"cosmosGeoPoint":90,"geoPoint":94,"contacts":11},"Orange","92866",{"type":72,"coordinates":91},[92,93],-117.85311,33.78779,{"lat":93,"lon":92},{"facility":64,"status":65,"city":96,"state":80,"zip":97,"country":69,"countryCode":70,"cosmosGeoPoint":98,"geoPoint":102,"contacts":11},"Pico Rivera","90660",{"type":72,"coordinates":99},[100,101],-118.09673,33.98307,{"lat":101,"lon":100},{"facility":64,"status":65,"city":104,"state":80,"zip":105,"country":69,"countryCode":70,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"San Diego","92103",{"type":72,"coordinates":107},[108,109],-117.16472,32.71571,{"lat":109,"lon":108},{"facility":64,"status":65,"city":112,"state":80,"zip":113,"country":69,"countryCode":70,"cosmosGeoPoint":114,"geoPoint":118,"contacts":11},"Upland","91786",{"type":72,"coordinates":115},[116,117],-117.64839,34.09751,{"lat":117,"lon":116},{"facility":64,"status":65,"city":120,"state":121,"zip":122,"country":69,"countryCode":70,"cosmosGeoPoint":123,"geoPoint":127,"contacts":11},"Hollywood","Florida","33024",{"type":72,"coordinates":124},[125,126],-80.14949,26.0112,{"lat":126,"lon":125},{"facility":64,"status":65,"city":129,"state":121,"zip":130,"country":69,"countryCode":70,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Maitland","32751",{"type":72,"coordinates":132},[133,134],-81.36312,28.62778,{"lat":134,"lon":133},{"facility":64,"status":65,"city":137,"state":138,"zip":139,"country":69,"countryCode":70,"cosmosGeoPoint":140,"geoPoint":144,"contacts":11},"Boston","Massachusetts","02116",{"type":72,"coordinates":141},[142,143],-71.05977,42.35843,{"lat":143,"lon":142},{"facility":64,"status":146,"city":147,"state":138,"zip":148,"country":69,"countryCode":70,"cosmosGeoPoint":149,"geoPoint":153,"contacts":11},"SUSPENDED","Watertown","02472",{"type":72,"coordinates":150},[151,152],-71.18283,42.37093,{"lat":152,"lon":151},{"facility":64,"status":65,"city":155,"state":156,"zip":157,"country":69,"countryCode":70,"cosmosGeoPoint":158,"geoPoint":162,"contacts":11},"Mount Kisco","New York","10549",{"type":72,"coordinates":159},[160,161],-73.72708,41.20426,{"lat":161,"lon":160},{"facility":64,"status":65,"city":164,"state":165,"zip":166,"country":69,"countryCode":70,"cosmosGeoPoint":167,"geoPoint":171,"contacts":11},"Avon Lake","Ohio","44012",{"type":72,"coordinates":168},[169,170],-82.0282,41.50532,{"lat":170,"lon":169},{"facility":64,"status":78,"city":173,"state":165,"zip":174,"country":69,"countryCode":70,"cosmosGeoPoint":175,"geoPoint":179,"contacts":11},"Westlake","44145",{"type":72,"coordinates":176},[177,178],-81.91792,41.45532,{"lat":178,"lon":177},{"facility":64,"status":65,"city":181,"state":182,"zip":183,"country":69,"countryCode":70,"cosmosGeoPoint":184,"geoPoint":188,"contacts":11},"Dallas","Texas","75251",{"type":72,"coordinates":185},[186,187],-96.80667,32.78306,{"lat":187,"lon":186},{"facility":64,"status":65,"city":190,"state":182,"zip":191,"country":69,"countryCode":70,"cosmosGeoPoint":192,"geoPoint":196,"contacts":11},"Houston","77030",{"type":72,"coordinates":193},[194,195],-95.36327,29.76328,{"lat":195,"lon":194},{"facility":64,"status":198,"city":199,"state":182,"zip":200,"country":69,"countryCode":70,"cosmosGeoPoint":201,"geoPoint":205,"contacts":11},"WITHDRAWN","Richmond","77407",{"type":72,"coordinates":202},[203,204],-95.76078,29.58218,{"lat":204,"lon":203},{"facility":64,"status":146,"city":207,"state":182,"zip":208,"country":69,"countryCode":70,"cosmosGeoPoint":209,"geoPoint":213,"contacts":11},"The Woodlands","77381",{"type":72,"coordinates":210},[211,212],-95.48938,30.15799,{"lat":212,"lon":211},{"facility":64,"status":65,"city":215,"state":216,"zip":217,"country":69,"countryCode":70,"cosmosGeoPoint":218,"geoPoint":222,"contacts":11},"Everett","Washington","98201",{"type":72,"coordinates":219},[220,221],-122.20208,47.97898,{"lat":221,"lon":220},{"type":224,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100576540",false,"NCT06786624","Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)","Key Inclusion Criteria:\n\n* Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.\n* Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.\n* Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.\n* Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score ≥22 at screening and at study baseline (Day 1).\n* Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.\n\nKey Exclusion Criteria:\n\n* A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.\n* Are considered by the investigator to be at imminent risk of suicide or injury to self or others.\n* Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.","ALL","18 Years",{"count":234,"type":235},200,"ESTIMATED","INTERVENTIONAL",[238],"PHASE3","The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.",[241],"Major Depressive Disorder",[243,244,241,31,48,245],"MDD","Depression","MADRS","2025-10-28",{"date":248,"type":249},"2025-10-29","ACTUAL",{"date":251,"type":249},"2025-01-22",{"date":253,"type":235},"2027-07",{"name":5,"class":6},18]